Company intelligence / Profile preview
Adjuvia Therapeutics
San Francisco, California, United Statesadjuviatx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Adjuvia Therapeutics develops novel orally administered therapeutics for rare and chronic diseases caused by mitochondrial and cellular dysfunction. Their lead compound, ATI‑103, uses a patented nanoparticle formulation of the antioxidant astaxanthin to protect cells from oxidative stress and regulate key cell signaling pathways. ATI‑103 is currently in IND-enabling studies with initial clinical focus on rare mitochondrial genetic disorders such as Friedreich’s Ataxia and Leigh Syndrome. The company was founded in 2023 by Dr. Laura Hix Glickman, John Carberry, and Tim Wilson.[1][3][6]
- Therapeutic areas
- Metabolic DisordersRare Diseases
- Modalities
- Small molecules (notably proprietary nanoparticle formulation of astaxanthin)[6]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Adjuvia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adjuvia Therapeutics.